Top Markets
Coin of the day
Beta Bionics, Inc. Beta Bionics, Inc.

Beta Bionics, Inc.

BBNX
株式のランク #10096
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated... Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
株価
$19.81
最終同期: 2026-08-28
時価総額
$891.32M
変化(1日)
1.39%
変化(1年)
5.16%
US
取引 Beta Bionics, Inc. (BBNX)

カテゴリー

Beta Bionics, Inc.(BBNX)の利益
2026 時点の利益 TTM: 0
Beta Bionics, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Beta Bionics, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
- -
DE